Jessica A. O'Hara

TL;DR: Colistin-resistant A. baumannii occurred almost exclusively among patients who had received CMS for treatment of carbapenem-resistant, colist in-susceptible, and -resistant isolates, suggesting evolution of resistance during CMS therapy.

TL;DR: Eight Klebsiella pneumoniae clinical strains with high-level aminoglycoside resistance were collected from eight hospitals in São Paulo State, Brazil, in 2010 and 2011 and five strains were found to produce a novel 16S rRNA methyltransferase, designated RmtG, which shared 57 to 58% amino acid identity with RmtD1 and Rmtd2.

TL;DR: It is suggested that regimens containing vancomycin may confer therapeutic benefit for infection due to colistin-resistant A. baumannii.

TL;DR: Isolates producing NDM-1 were first reported in the United States in 2010, followed by several case reports and most recently a hospital outbreak in Colorado (3–6), and as for OXA-48-group β-lactamase, 2 cases of infection with OXa-48–producing K. pneumoniae were recently reported from Virginia (7).

TL;DR: Air and clinical isolates were found to be clonally related anderosolization of A. baumannii in the ICUs is a concern, and its role in the transmission of this organism among patients should be further clarified.